 Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal GI diseases, today announced that the United States Patent and Trademark Office USPTO issued a Notice of Allowance for the GimotiTM trademark. Gimoti is Evokes nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. The U.S. Food and Drug Administration FDA is currently reviewing the New Drug Application NDA for Gimoti and has set a target goal date under the Prescription Drug User Fee Act PDUFA of June 19, 2020. 